Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease

2015-03-06

Inflammatory Bowel Diseases , Volume 21 - Issue 4 p. 951- 961

Additional Metadata
Keywords	biologic therapies, immunomodulators, inflammatory bowel disease, pediatric
Persistent URL	doi.org/10.1097/MIB.0000000000000245, hdl.handle.net/1765/88112
Journal	Inflammatory Bowel Diseases
Organisation	Department of Pediatrics
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Cozijnsen, M., Escher, J., Griffiths, A., Turner, D., & de Ridder, L. (2015). Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. Inflammatory Bowel Diseases (Vol. 21, pp. 951–961). doi:10.1097/MIB.0000000000000245

Publication